---
title: "Mounjaro, Wegovy & ADHD"
date: 2026-06-14T14:54:00+01:00
author: Paulina Charlesworth
canonical_url: "https://drcharlesworth.co.uk/journal/mounjaro-wegovy-adhd-beyond-weight-loss-mood-and-longevity"
section: Journal Articles
---
Weight Loss, Mood and Longevity

## More Than Just Weight Loss

The conversation around weight-loss injections like **Mounjaro (tirzepatide)** and **Wegovy (semaglutide)** often focuses on kilograms lost. In clinical trials:

- **Wegovy (STEP-1 trial, NEJM 2021):** ~15% average body weight loss over 68 weeks.
- **Mounjaro (SURMOUNT-1 trial, NEJM 2022):** ~21% average weight loss at higher doses, with some patients in my own clinic losing over 30%.

But science — and real-world patient feedback in Sevenoaks — shows the benefits reach far beyond the scales.

Mood, Focus & ADHD-Like Benefits

**Neuroinflammation & mood:** Animal studies show semaglutide reduces brain inflammation, improving behaviour linked to anxiety and depression.

**Large-scale human data:** A 2023 study of nearly 30,000 patients found GLP-1 medicines were linked with fewer depressive symptoms, independent of weight loss.

**Cognitive protection:** Long-term cohort data suggest lower risks of dementia, stroke, and early death in people taking GLP-1s, likely via vascular and inflammatory improvements.

**Real-world patient reports:**

- Feeling calmer, more focused, less impulsive
- Reduced “food noise” and obsessive food thoughts
- Fewer late-night online purchases
- Less reliance on alcohol or smoking

**Why?** GLP-1 receptors are present in the brain’s **dopamine reward pathways** (van Bloemendaal et al., Diabetes Obes Metab, 2014). By modulating dopamine, these medicines may reduce cravings and impulsive behaviours — explaining why many patients feel more in control, not just around food but in everyday life.

Inflammation: The Hidden Driver

Obesity is the **number one preventable cause of cancer in the UK** (World Cancer Research Fund), largely because of chronic inflammation.

- **Wegovy:** A 2024 meta-analysis of >26,000 patients confirmed significant reductions in C-reactive protein (CRP) and inflammatory cytokines (IL-6, TNF-α).
- **Mounjaro:** Early data suggest even greater anti-inflammatory effects, thanks to its dual GLP-1/GIP mechanism, with reductions in CRP, IL-6, and improved vascular health.

Patients often describe this as “feeling lighter” — more energy, fewer aches, and greater resilience.

Lifestyle Ripple Effects

GLP-1 therapy can shift behaviour in surprising ways:

- **Less alcohol and smoking:** Early studies and real-world observations show patients cut back naturally, sometimes dramatically.
- **Better sleep:** Weight reduction and inflammation improvements help ease sleep apnoea. A 2024 tirzepatide trial showed up to **60% reduction in apnoea–hypopnoea index scores**.
- **Spending patterns:** Many patients say treatment feels “cost-neutral” — they spend less on takeaways, alcohol, snacks, and even impulse shopping.

These changes reinforce long-term health gains and reduce reliance on medication over time.

Cardiovascular & Longevity Benefits

- **Semaglutide:** In the SELECT trial (2023), semaglutide reduced major cardiovascular events (heart attack, stroke, CV death) by **20%** in overweight patients without diabetes.
- **Tirzepatide:** Early trial data suggest even stronger effects on blood sugar and metabolic control, with the SURPASS-CVOT outcomes trial underway.

Both drugs therefore sit at the intersection of **weight management, longevity, and cardiovascular medicine**.

Practical Comparison

BENEFIT AREAWEGOVY (SEMAGLUTIDE)MOUNJARO (TIRZEPATIDE)**Weight loss**~15% avg (STEP-1)~21% avg (SURMOUNT-1); some >30%**Mood & cognition**Evidence: fewer depression & anxiety symptomsAnecdotal: calm, focus, impulse control**Inflammation**Reduces CRP, IL-6, TNF-αStrong reductions in CRP, IL-6; dual action may be stronger**Cardiovascular**SELECT trial: ↓20% CV riskOngoing CVOT; early signals promising**Sleep**No major trial yet2024 trial: improved sleep apnoea**Off-label observations**Mood & neuroprotectionADHD-style calm, less alcohol/smoking, cost-neutralityOff-Label Use & Safety Disclaimer

Some of the benefits described — ADHD-style calm, alcohol reduction, microdosing for inflammatory support — are **off-label uses**. These are only considered after a **full medical consultation**, where we discuss individual risks, benefits, and licensed alternatives for each patient.

Every treatment plan is **bespoke and doctor-led**, with careful monitoring to keep you safe.

Why This Matters for You

If you’re considering **medical weight loss consultation in Sevenoaks**, your decision is about more than body weight. These treatments can:

- Improve **mental clarity and mood**
- Reduce **inflammation and cancer risk**
- Support **heart health and sleep**
- Reinforce healthier **lifestyle patterns**

When delivered in a structured clinic setting, GLP-1 medicines become not just weight-loss tools, but part of **longevity medicine**.